Blocks drug companies from 'product hopping' to boost generic competition.
This bill would stop drug manufacturers from using a tactic called 'product hopping' to delay cheaper generic and biosimilar drugs. It would give the Federal Trade Commission new powers to stop these actions and seek financial penalties, aiming to bring more affordable medicines to consumers faster.
Today, drug companies can sometimes use 'product hopping' tactics to delay cheaper generic or biosimilar drugs from entering the market, without specific prohibitions under the Federal Trade Commission Act. If this bill becomes law, it would explicitly ban these practices, giving the Federal Trade Commission new tools to stop them and potentially recover ill-gotten gains, aiming to speed up the availability of more affordable medicines.
S 1040 · 119th Congress · AI Summary by gemini-2.5-flash · 8/10
Sign in to see your representatives' phone numbers
60 filings mentioned this bill
Amounts reflect total quarterly lobbying spend reported to the Senate, not bill-specific spending. Source: Senate LDA filings.